| Chronic Lymphocytic Leukemia
Jaypirca vs Zydelig
Side-by-side clinical, coverage, and cost comparison for chronic lymphocytic leukemia.Deep comparison between: Jaypirca vs Zydelig with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsZydelig has a higher rate of injection site reactions vs Jaypirca based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Zydelig but not Jaypirca, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Jaypirca
Zydelig
At A Glance
Oral
Once daily
BTK inhibitor
Oral
Twice daily
PI3K-delta inhibitor
Indications
- Mantle cell lymphoma
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Chronic Lymphocytic Leukemia
Dosing
Mantle cell lymphoma 200 mg orally once daily until disease progression or unacceptable toxicity; swallow tablets whole with water, with or without food.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma 200 mg orally once daily until disease progression or unacceptable toxicity; swallow tablets whole with water, with or without food.
Chronic Lymphocytic Leukemia 150 mg orally twice daily with or without food until disease progression or unacceptable toxicity; dose reductions to 100 mg twice daily apply after interruption for certain adverse reactions.
Contraindications
—
- History of serious hypersensitivity reactions to idelalisib, including anaphylaxis
- History of toxic epidermal necrolysis with any drug
Adverse Reactions
Most common (>=30%) Decreased neutrophil count, decreased hemoglobin, decreased leukocytes, fatigue, decreased platelets, decreased lymphocyte count, calcium decreased
Serious Pneumonia, COVID-19, sepsis, febrile neutropenia, hemorrhage, pleural effusion
Most common (>30%) Diarrhea, pneumonia, pyrexia, fatigue, rash, cough, nausea
Serious Hepatotoxicity, severe diarrhea or colitis, pneumonitis, infections (including sepsis, CMV, PJP), intestinal perforation, severe cutaneous reactions, hypersensitivity reactions, neutropenia
Postmarketing Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms
Pharmacology
Pirtobrutinib is a small molecule, noncovalent inhibitor of BTK, a signaling protein of the B-cell antigen receptor and cytokine receptor pathways; it binds wild-type BTK and BTK harboring C481 mutations to inhibit BTK kinase activity and suppress malignant B-cell proliferation.
PI3K-delta inhibitor; idelalisib blocks BCR, CXCR4, and CXCR5 signaling pathways to induce apoptosis and inhibit proliferation in normal and malignant B-cells, and reduces chemotaxis and adhesion of lymphoma cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Jaypirca
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (12/12)
Zydelig
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Jaypirca
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (1/8) · Qty limit (2/8)
Zydelig
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Jaypirca
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Zydelig
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableCancerCare: Chronic Lymphocytic Leukemia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$5/momo
Zydelig Access Connect Copay Coupon CardCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
JaypircaView full Jaypirca profile
ZydeligView full Zydelig profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.